Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Pharmacokinetic of Oseltamivir in Healthy Obese Thai Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy as judged by a responsible physician with no abnormality identified on a medical evaluation including medical history and physical examination.~* Males and Females aged between 18 years to 60 years.~* BMI \>30 kg/ m2 (BMI = body weight \[BW\] (kg)/height (m2)) for obese group, BMI 18-24.9 kg/ m2 (BMI = BW (kg)/height (m2)) for control group.~* A female is eligible to enter and participate in this study if she is:~  * of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or double oophorectomy~ * or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone levels \>40 mIU/mL or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy~ * or of childbearing potential, has a negative serum pregnancy test at screening and prior to start the study drug in each period, and abstain from sexual intercourse or agrees to using effective contraceptive methods during the study until completion of the follow-up procedures~* A male is eligible to enter and participate in this study if he: agrees to abstain from (or use a condom during) sexual intercourse with females of childbearing potential or lactating females; or is willing to use a condom/spermicide, during the study until completion of the follow-up procedures.~* Read, comprehend, and write at a sufficient level to complete study-related materials.~* Provide a signed and dated written informed consent prior to study participation.~* Normal electrocardiogram (ECG) with QTc \<450 msec.~* Willingness and ability to comply with the study protocol for the duration of the trial.~Exclusion Criteria:~* Females who are pregnant, trying to get pregnant, or are lactating.~* The subject has evidence of active substance abuse that may compromise safety, pharmacokinetics, or ability to adhere with protocol instructions.~* A positive pre-study hepatitis B surface antigen, positive hepatitis C antibody, or positive human immunodeficiency virus-1 (HIV-1) antibody result at screening.~* Subjects with a personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or additional risk factors for torsades de points (heart failure, hypokalemia).~* Subjects with a family history of sudden cardiac death.~* A creatinine clearance \<70 mL/min as determined by Cockcroft-Gault equation:~CLcr (mL/min) = (140 - age) \* Wt / (72 \* Scr) (multiply answer by 0.85 for females). Where age is in years, weight (wt) is in kg, and serum creatinine (Scr) is in units of mg/dL \[Cockcroft, 1976\].~* History of alcohol or substance abuse or dependence within 6 months of the study: History of regular alcohol consumption averaging \>7 drinks/wk for women or \>14 drinks/wk for men. One drink is equivalent to 12 g alcohol = 5 oz (150 mL) of wine or 12 oz (360 mL) of beer or 1.5 oz (45 mL) of 80 proof distilled spirits within 6 months of screening.~* Use of prescription or non-prescription drugs except paracetamol at doses of up to 2 grams/day, including vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication until the completion of the follow-up procedure.~* Use of live attenuated influenza vaccine, inactivated influenza vaccine, or any other antiinfluenza antiviral medications within 14 days prior to the first dose of investigational product.~* The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of study medication.~* The subject is unwilling to abstain from ingesting alcohol within 48 hours prior to the first dose of study medication until collection of the final pharmacokinetic sample during each regimen.~* Subjects who have donated blood to the extent that participation in the study would result in more than 300 mL blood donated within a 30-day period.~* Subjects who have a history of allergy to the study drug or drugs of this class, or a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation in the trial. In addition, if heparin is used during pharmacokinetic sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.~* Subjects with unstable medical conditions that, in the opinion of the investigator would compromise their participation in the trial~* Those who, in the opinion of the investigator, have a risk of non-compliance with study procedures.~* Lack of suitability for participation in this study, for any reason, in the opinion of the investigator.~* AST or ALT \>1.5 upper limit of normal (ULN)~* Subjects with history of renal disease, hepatic disease, and/or cholecystectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Regimen A (Type: EXPERIMENTAL): oseltamivir 75 mg single dose
- Regimen B (Type: ACTIVE_COMPARATOR): oseltamivir 150 mg single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete